Stifel Nicolaus Initiates Coverage on Concert Pharmaceuticals Inc (CNCE)
Posted on July 1, 2016 by Stefani Robinson in Analyst Articles - US, Investing
Concert Pharmaceuticals logoAnalysts at Stifel Nicolaus started coverage on shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) in a report issued on Friday. The brokerage set a “buy” rating and a $23.00 price target on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 104.81% from the company’s previous close.
More at sleekmoneyDOTcom
Just realized this study uses D/Q (Nuedexta)...it is not the '786 trial (which is placebo controlled and unlikely to have any interim data at any point). Still, results will be a great look into the future of the '786 study.
No data out yet I know of. I'd watch twitter and press releases late in the day but this probably is not big enough to get attention. The presentation is 3:30-5PM (long duration suggests its a poster). You can see the title etc if you go to the APA website and download the program. There are a number of other D/Q PBA related abstracts also in that program. Here's the schizophrenia one:
Management of Schizophrenia
3:30 p.m. – 5:00 p.m.
Room B406, Level 4
Georgia World Congress Center
1. Treatment of Negative
Symptoms of Schizophrenia With
Augmentation of Antipsychotics: An
Open Trial in 42 Patients
Paul J. Markovitz, M.D., Ph.D.
Avanir will present data on the first 42 patients in this trial at the APA conference today. I'd think they must find results interesting to present so early. Also, nice recruitment pace to have data on 42 already (120 pt trial).
It didn't like the references but the first author on both is L. Nguyen and if you search her with dextromethorphan and depression they should come up.
Yahoo keeps deleting my response. Short notes:
I did see it
As you likely saw, it shows ketamine's effect seems to be via AMPA in those (mouse) models
DM also works the same way in the same models + S1R effects
references to follow if they don't delete this
Hi Harry/Dairyman...I certainly remember you from the good old AVNR days.
I already follow AVXL fairly closely. I find it a fascinating stock and about as high risk/high reward as they come. I've had small positions for short times when they've bottomed out. I think this may be an ok entry point at current levels but they have all their Lincoln Park financing yet to come which will put pressure on the stock and their P II data is quite delayed for no good reason I can see. Their data and patient stories have some interesting tidbits and maybe they will be a huge success at some point but for now I really don't see much to give any more than a glimmer of hope and I greatly distrust management. Until there's real data of substance, the SEC investigation ends, and dilutive financing is further along I expect I'll be on the sidelines.
I'll call this rumor because I can't find anywhere to verify it...including sec.gov (for now). But the following tweet just came through:
Insider Alert: Tung Roger D [Chief Executive Officer] buys $CNCE for 207K
3:21 PM - 12 May 2016
For those how missed it...the same author wrote another nice follow up article on CNCE. Worth looking at.
Crazy pps...major overreaction IMO